Related Experiment Video
Updated: Feb 4, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Cardiovascular disease and COPD: dangerous liaisons?
Klaus F Rabe1,2, John R Hurst3, Samy Suissa4,5
1Dept of Medicine, University of Kiel, Kiel, Germany k.f.rabe@lungenclinic.de.
Insights
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) often coexist, worsening patient outcomes. While some COPD treatments may offer cardiovascular benefits, more research is needed on their impact on cardiovascular events and safety.
Area of Science:
- Pulmonology
- Cardiology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist.
- This comorbidity is linked to poorer health outcomes compared to individual conditions.
- Shared pathophysiological mechanisms include systemic inflammation and lung hyperinflation.
Purpose of the Study:
- To review the cardiovascular (CV) effects of COPD treatments.
- To examine the CV safety and outcomes of specific COPD pharmacotherapies.
- To discuss the impact of cardiovascular medications on COPD management.
Main Methods:
- Literature review of studies investigating COPD and CVD.
- Analysis of evidence on bronchodilators and their CV effects.
- Evaluation of safety data for long-acting bronchodilators and beta-blockers in COPD patients.
Main Results:
- Long-acting bronchodilators may improve arterial stiffness and cardiac function, but CV outcome benefits require further study.
- Some evidence suggests a transient increase in CV event risk with long-acting bronchodilators at treatment initiation.
- Beta-blockers are generally safe in COPD, and patients should not be denied them due to unwarranted concerns about bronchospasm.
Conclusions:
- Coexisting COPD and CVD necessitate integrated management strategies.
- Further research is needed to clarify the CV benefits and risks of COPD pharmacotherapies.
- Clearer guidelines are required for managing comorbid CVD in COPD patients to ensure timely and appropriate interventions.
Abstract:
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently occur together and their coexistence is associated with worse outcomes than either condition alone. Pathophysiological links between COPD and CVD include lung hyperinflation, systemic inflammation and COPD exacerbations. COPD treatments may produce beneficial cardiovascular (CV) effects, such as long-acting bronchodilators, which are associated with improvements in arterial stiffness, pulmonary vasoconstriction, and cardiac function. However, data are limited regarding whether these translate into benefits in CV outcomes. Some studies have suggested that treatment with long-acting β2-agonists and long-acting muscarinic antagonists leads to an increase in the risk of CV events, particularly at treatment initiation, although the safety profile of these agents with prolonged use appears reassuring. Some CV medications may have a beneficial impact on COPD outcomes, but there have been concerns about β-blocker use leading to bronchospasm in COPD, which may result in patients not receiving guideline-recommended treatment. However, there are few data suggesting harm with these agents and patients should not be denied β-blockers if required. Clearer recommendations are necessary regarding the identification and management of comorbid CVD in patients with COPD in order to facilitate early intervention and appropriate treatment.
More Related Videos
Related Concept Videos
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:14Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...